GSK's concedes defeat over MAGE-A3 in lung cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has decided to drop its MAGE-A3 cancer vaccine in non-small cell lung cancer (NSCLC). The Phase III MAGRIT trial of MAGE-A3 is being terminated as it "will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment," said GSK.